Previous month:
November 2016
Next month:
March 2017

Aclaris JAK inhibitor research for baldness ATI-5001, ATI-5002, ATI-5003 is progressing

Aclaris JAK inhibitor DrAlanBauman

ACLARIS Therapeutics JAK Inhibitor Research on Androgenetic Alopecia, male and female pattern baldness is progressing

Below you will find an excerpt from an Edited Transcript of Aclaris Therapeutics Inc earnings conference call or presentation Thursday, November 3, 2016 at 12:30:00pm GMT:

I will now turn the call over to Dr. Stuart Shanler to give a brief update on the JAK inhibitor program in alopecia areata, vitiligo and androgenetic alopecia. Stu?

--------------------------------------------------------------------------------

Stuart Shanler, Aclaris Therapeutics, Inc. - Chief Scientific Officer [4]

--------------------------------------------------------------------------------

Thanks, Neal. Our JAK program continues to progress as expected with ATI-5001 for oral administration for the treatment of the most severe forms of alopecia areata -- that's alopecia totalis and alopecia universalis -- and ATI-5002 for topical administration, primarily for the patchy forms of alopecia areata.

We are pleased to report that the IND application for ATI-5001 has been submitted to the FDA, and we expect to begin a human pharmacokinetic/pharmacodynamic -- that's a PK/PD study -- before the end of this year, which is slightly ahead of schedule. For the topical version, the ATI-5002, we are on track to submit an IND application and begin a clinical trial in the first half of 2017, which is consistent with our previous guidance.

In addition to progressing our JAK treatment program for the treatment of alopecia areata and as we reported on our last call, we have initiated preclinical development of additional JAK inhibitors which we are developing for topical use both in vitiligo and androgenetic alopecia, which is also known as male or female pattern baldness. The program includes the development of ATI-5003, which is a covalently binding JAK3-specific inhibitor, and the preclinical and formulation work continue to progress as expected.

At Bauman Medical Group Hair Transplant and Hair Loss Treatment Center in Boca Raton, FL we will be keeping a close eye on this groundbreaking hair loss research as it progresses. 


New Beauty Treatments - Hair and Skin Care Medical TreatmentsAuthor

Screen Shot 2016-12-27 at 1.35.31 PM
"If a follicle can be encouraged to produce a thicker hair, often pigment will also ramp up," says Alan J. Bauman, MD, of an unexpected—but welcome—side effect of stimulating hair growth. "Using minoxidil can make more pigment deep in the hair fiber. It's not going to reverse completely gray hair, but hair can get thicker and darker."

via www.elle.com

When a hair follicle is weakened by age, heredity and other risk factors, the fiber diameter, length and pigmentation can diminish. Using treatments like Formula 82M minoxidil, Laser Therapy or PRP can help improve the follicle function and hair regrowth, producing a thicker, longer, more pigmented hair over time. --Dr. Alan Bauman - Bauman Medical Group - Formula 82M Minoxidil